Brief: Inovio To Begin Rolling Submission Of BLA For Ino-3107 For The Treatment Of RRP In Adults
26/08/2025 13:07
Aug 26 (Reuters) - Inovio Pharmaceuticals Inc INO.O: INOVIO TO BEGIN ROLLING SUBMISSION OF BLA FOR INO-3107 FOR THE TREATMENT OF RRP IN ADULTS INOVIO PHARMACEUTICALS INC - BLA SUBMISSION ON TRACK FOR 2H25, FDA ACCEPTANCE BY END 2025 Source text: ID:nPnc1kJ8ma Further company coverage: INO.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Inovio Pharmaceuticals
See all newsBrief: Inovio Announces Favorable Judgment In Litigation With Vgxi, Inc. And Geneone Life Science
U.S. RESEARCH ROUNDUP-Airbnb, Five Below, Silgan Holdings
Inovio Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Inovio Q2 net loss narrows on warrant gain, lower costs
Brief: Inovio Pharmaceuticals Q2 Operating Expenses USD 18.6 Million